Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.

While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.

GSK already partners with Vectura on respiratory therapies, but the British pharma giant could be looking to take the relationship one step further.

Good news for pharma's pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, a new analysis shows.

McCann Health tapped its first global chief digital officer, highlighting an increase in digital business from pharma clients.

As investigations in the Philippines proceed, Sanofi Pasteur has agreed to refund the cost of unused Dengvaxia doses worth about $28 million.

The risk of biosimilar competition to Roche's top cancer meds prompted one analyst to warn investors to “brace for impact.”

The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.